21. November 2009 02:07
Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders.
[More]
21. November 2009 00:45
Long durations of exposure to formaldehyde used for embalming in the funeral industry were associated with an increased risk of death from myeloid leukemia, according to a new study published online November 20 in the Journal of the National Cancer Institute.
[More]
20. November 2009 08:04
Sabrina Cohen, founder of The Sabrina Cohen Foundation for Stem Cell Research (SCF), was just recognized as a WebMD 2009 Health Hero. She will receive national media attention with a full-page article about her personal story of triumph and courage, and shares the spotlight with celebrity movie-star, Scarlett Johansson and other Health Heroes in the November/December issue.
[More]
20. November 2009 02:08
A team led by Penn State's Ross Hardison, T. Ming Chu Professor of Biochemistry and Molecular Biology, has taken a large step toward unraveling how regulatory proteins control the production of gene products during development and growth.
[More]
19. November 2009 10:37
Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications.
[More]
0f477df3-7276-483a-9f16-5c5e959136a1|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Antisense, Apoptosis, Biotechnology, Cancer, Cell, Chemotherapy, Hepatocellular Carcinoma, Leukemia, Lymphoma, Oncology, Sorafenib
19. November 2009 06:00
Researchers at the University of Alabama at Birmingham (UAB) have uncovered the genetic identity of a cellular receptor for the immune system's first-response antibody, a discovery that sheds new light on infection control and immune disorders. The discovery is such a crucial part of immunology that UAB researchers, in conjunction with Japanese researchers, are asking that the gene linked to this antibody receptor be renamed to better describe its role in early immune responses.
[More]
19. November 2009 03:13
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).
[More]
7169822c-90e7-4db1-bb27-26e0162bbe54|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cancer, Cell, Chemotherapy, Chronic Lymphocytic Leukemia, Cough, Cyclophosphamide, Headache, Hepatitis B, Leukemia, Lymphoma, MabThera, Methotrexate, Multiple Sclerosis, Nausea, Rheumatoid Arthritis, Rituximab, Virus
18. November 2009 09:14
CytRx Corporation, a biopharmaceutical company, today announced plans to initiate an open-label, multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a second-line treatment in patients with advanced gastric (stomach) cancer.
[More]
22d7d56a-040a-4b79-b687-06869cbedf35|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Anemia, Cancer, Cell, Chemotherapy, Doxorubicin, Dysplasia, Epirubicin, Gastritis, Helicobacter pylori Infection, Investment, Leukemia, Oncology, Smoking, Stomach Cancer, Tobacco
18. November 2009 08:40
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models.
[More]
7105e9d6-13ab-4fd4-afa9-3e55eccba03a|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Acute Lymphoblastic Leukemia, Apoptosis, Breast Cancer, Cancer, Cell, Chronic Myeloid Leukemia, Colon Cancer, Erlotinib, Gleevec, Hospital, Leukemia, Lung Cancer, Lymphoma, Melanoma, Multiple Myeloma, Myeloid Leukemia, Non-Small Cell Lung Cancer, Oncology, Paclitaxel, Pancreatic Cancer, Prostate Cancer, Small Cell Lung Cancer, Sunitinib, Tarceva, Xenograft
18. November 2009 05:59
Research and Markets (http://www.researchandmarkets.com/research/44c77e/chronic_myelogenou) has announced the addition of Decision Resources, Inc.'s new report "Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec" to their offering.
[More]
18. November 2009 04:13
Asuragen, Inc. announced today that it has entered into an exclusive agreement with Life Technologies Corporation to develop and distribute worldwide an in-vitro diagnostic test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML).
[More]
17. November 2009 05:02
To highlight results of more recent research, the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference will host a press briefing on "Drugs in the Pipeline." Sara A. Courtneidge, Ph.D., D.Sc., professor and director of the Tumor Microenvironment Program, and director of academic affairs at the Burnham Institute for Medical Research, will moderate this press briefing.
[More]
ac48c877-eb35-45fc-9d99-0eb9b9d6de31|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Acetylation, Adenosine, Amino Acid, Anemia, Angiogenesis, Autophagy, Blood Pressure, Breast Cancer, Cancer, Cediranib, Cell, Chemotherapy, Colorectal Cancer, Diarrhea, DNA, Gene Expression, Hematology, Leukemia, Myeloid Leukemia, Nausea, Oncology, Ovarian Cancer, Radiotherapy, Stem Cell, Stress, Vomiting
16. November 2009 10:02
Cord Blood America, Inc., the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that its 10Q filing with the U.S. SEC for the three and nine-month period ended September 30, 2009, confirmed its announcements throughout 2009 that it is significantly reducing debt.
[More]
16. November 2009 09:12
Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.
[More]
16. November 2009 07:37
EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported results for the three- and nine-month periods ending September 30, 2009.
[More] 
Subscribe